On 2 April 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) announced it will deepen cooperation with the U.S. Food and Drug Administration (FDA) to speed access to safe medical devices in both countries. The move follows a wider U.S.–UK pharmaceutical partnership that removed tariffs on UK medicines and encourages early launches. The regulators will work on aligning medical‑device regulations, including exploring mutual‑recognition mechanisms, reducing duplication for manufacturers and streamlining approval pathways. Both agencies will keep independent oversight and maintain strict safety standards. The partnership is intended to give UK MedTech companies clearer, more predictable routes to market and help patients receive innovative diagnostics and devices sooner in the UK and the U.S.
© Crown copyright, 2024, GOV.UK.
Summary adapted from content licensed under the Open Government Licence v3.0.
For details, see https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Original source: https://www.gov.uk/
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.